Inhibitors of advanced glycation end product-associated protein cross-linking

被引:33
作者
Lehman, TD [1 ]
Ortwerth, BJ [1 ]
机构
[1] Univ Missouri, Sch Med, Mason Eye Inst, Columbia, MO 65212 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2001年 / 1535卷 / 02期
关键词
glycation; protein cross-linking; L-threose; advanced glycation end product; cataract; reducing agent; 2-aminoguanidine; metabisulfite;
D O I
10.1016/S0925-4439(00)00087-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The reaction of lens proteins with sugars over time results in the formation of protein-bound advanced glycation end products (AGEs). The most damaging element of AGE formation may be the synthesis of protein-protein cross-links in long-lived proteins, such as collagen or lens crystallins. A quantitative cross-linking assay, involving the sugar-dependent incorporation of [U-C-14]lysine into protein, was employed to determine the efficacy of a variety of potential cross-linking inhibitors. Reaction mixtures contained 5.0 mM L-threose, 2.5 mu Ci [C-14]lysine (1.0 mCi/mmole), 5.0 mg/ml bovine lens proteins, 0-10 mM inhibitor and 1.0 mM DTPA in 100 mM phosphate buffer, pH 7.0. Of 17 potential inhibitors tested, 11 showed 50% inhibition or less at 10 mM. The dicarbonyl-reactive compounds 2-aminoguanidine, semicarbazide and o-phenylenediamine inhibited 50% at 2.0 mM, whereas 10 mM dimethylguanidine had no effect. Several amino acids failed to compete effectively with [C-14]lysine in the cross-linking assay; however, cysteine inhibited 50% at 1.0 mM, This was likely due to the sulfhydryl group of cysteine, because 3-mercaptopropionic acid and reduced glutathione exhibited similar activity. Sodium metabisulfite had the highest activity, inhibiting 50% at only 0.1-0.2 mM. Protein dimer formation, as determined by SDS-PAGE, was inhibited in a quantitatively similar manner. The dicarbonyl-reactive inhibitors and the sulfur-containing compounds produced similar inhibition curves for [C-14]lysine incorporation over a 3 week assay with 250 mM glucose. A much lesser effect was observed on either the incorporation of [C-14]glucose, or on fluorophore formation (360/420 nm), suggesting that non-cross-link fluorophores were also formed. The inhibitor data were consistent with cross-linking by a dicarbonyl intermediate. This was supported by the fact that the inhibitors were uniformly less effective when the 5.0 mM threose was replaced by either 3.0 mM 3-deoxythreosone or 3.0 mM threosone. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:110 / 119
页数:10
相关论文
共 46 条
[1]  
BAYNES JW, 1984, METHOD ENZYMOL, V106, P88
[2]   Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: Comparison with aminoguanidine [J].
Booth, AA ;
Khalifah, RG ;
Hudson, BG .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 220 (01) :113-119
[3]   Advanced glycosylation end products in diabetic renal and vascular disease [J].
Bucala, R ;
Vlassara, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (06) :875-888
[4]   Preventive aspirin treatment of streptozotocin induced diabetes: blockage of oxidative status and revertion of heme enzymes inhibition [J].
Caballero, F ;
Gerez, E ;
Batlle, A ;
Vazquez, E .
CHEMICO-BIOLOGICAL INTERACTIONS, 2000, 126 (03) :215-225
[5]  
CAMERON NE, 1995, N-S ARCH PHARMACOL, V352, P685
[6]   POLYMERIZATION OF ACETYLATED LYSOZYME AND IMPAIRMENT OF THEIR AMINO-ACID-RESIDUES DUE TO ALPHA-DICARBONYL AND ALPHA-HYDROXYCARBONYL COMPOUNDS [J].
CHO, RK ;
OKITANI, A ;
KATO, H .
AGRICULTURAL AND BIOLOGICAL CHEMISTRY, 1986, 50 (06) :1373-1380
[7]   Antioxidant properties of aminoguanidine [J].
Courderot-Masuyer, C ;
Dalloz, F ;
Maupoil, V ;
Rochette, L .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (05) :535-540
[8]   Prevention of lens protein glycation by taurine [J].
Devamanoharan, PS ;
Ali, AH ;
Varma, SD .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1997, 177 (1-2) :245-250
[9]   MECHANISTIC STUDIES OF ADVANCED GLYCOSYLATION END-PRODUCT INHIBITION BY AMINOGUANIDINE [J].
EDELSTEIN, D ;
BROWNLEE, M .
DIABETES, 1992, 41 (01) :26-29
[10]   Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II) [J].
Freedman, BI ;
Wuerth, JP ;
Cartwright, K ;
Bain, RP ;
Dippe, S ;
Hershon, K ;
Mooradian, AD ;
Spinowitz, BS .
CONTROLLED CLINICAL TRIALS, 1999, 20 (05) :493-510